Tetra Bio-Pharma Inc. TBPMF TBP announced Thursday it has completed bought deal financing, selling a total of 29.25 million corporation units at a price of CA$0.53 (40 cents) per unit for aggregate gross proceeds of CA$15.5 million ($11.6 million).
Echelon Wealth Partners Inc. led the offering and acted as an exclusive underwriter and book runner.
Each unit consisted of one common share and one common share purchase warrant, with each warrant granting the holder with the option to buy one common share at a price of CA$0.75 until Feb. 13, 2023, according to Tetra Bio-Pharma.
The company said it plans to use the capital to support further growth in its clinical program and for general corporate purposes.
Tetra Bio-Pharma is a cannabinoid-focused biopharmaceutical company that runs a Health Canada-approved clinical program designed to deliver new prescription drugs and treatment to patients.
Tetra Bio-Pharma shares were trading 2.93% higher at 33 cents at the time of publication Thursday.
Benzinga's Cannabis Capital Conference returns to Miami Feb. 24-25 with North America's largest B2B cannabis gathering, bringing together capital, cannabis executives, thought leaders and more!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.